Table 1. Baseline demographic and clinical characteristics.
Demographics | Total group | Low-group | High-group | P-value |
---|---|---|---|---|
N = 24 | ≤ Median TAC dose | > Median TAC dose | ||
N = 12 | N = 12 | |||
Age at HT (years) | 55.8 ±2.3 | 55.2 ±3.6 | 56.3 ±3.2 | 0.82 |
Male (n, %) | 21 (87.5) | 10 (83.3) | 11 (91.7) | 1.0 |
Race | 0.12 | |||
White (n, %) | 15 (62.5) | 10 (83.3) | 5 (41.7) | |
Black (n, %) | 7 (29) | 2 (16.7) | 5 (41.7) | |
Other (n, %) | 2(8) | 0 | 2 (16.7) | |
BMI, Mean ± SE | 25.9 ±0.9 | 27.7 ±1.5 | 24.1 ±0.7 | 0.05 |
Diabetes (n, %) | 10 (41.7) | 5 (41.7) | 5 (41.7) | 1.0 |
AFib (n, %) | 13 (54.1) | 8 (66.7) | 5 (41.7) | 0.41 |
Hyptertension (n, %) | 17 (70.8) | 8 (66.7) | 9 (75) | 1.0 |
LVAD prior to HT (n, %) | 18 (75) | 8 (66.7) | 10 (83.3) | 0.64 |
Time post-transplant (days) | 63.5 ±5.9 | 65.1±8.2 | 61.8±8.8 | 0.79 |
Laboratory Values | ||||
Creatinine, mg/dL | 1.34 ±0.11 | 1.32 ±0.17 | 1.37 ±0.14 | 0.74 |
AST, U/L | 26.9 ±2.7 | 29.3 ±3.8 | 23.6 ±3.5 | 0.37 |
Total Bilirubin, mg/dL | 0.56 ±0.11 | 0.48 ±0.11 | 0.66 ±0.22 | 0.35 |
Medications | ||||
Mycophenolate Mofetil (n, %) | 20 (83.3) | 8 (66.7) | 12 (100) | 0.09 |
Nystatin (n, %) | 21 (87.5) | 9 (75) | 12 (100) | 0.22 |
Valgancyclovir (n, %) | 11 (45.8) | 5 (41.7) | 6 (50) | 1.0 |
Trimethoprim/ sulfamethoxazole (n, %) | 16 (66.7) | 8 (66.7) | 8 (66.7) | 1.0 |
Dapsone (n, %) | 7 (29.2) | 2 (16.7) | 5 (41.7) | 0.37 |
Antibiotics (n, %)* | 22 (91.6) | 11 (91.6) | 11 (91.6) | 1.0 |
Aspirin (n, %) | 20 (83.3) | 10 (83.3) | 10 (83.3) | 1.0 |
Loop Diuretics (n, %) | 12 (50) | 6 (50) | 6 (50) | 1.0 |
Statins (n, %) | 21 (87.5) | 9 (75) | 12 (100) | 0.21 |
Proton Pump Inhibitors (n, %) | 14 (58.3) | 7 (58.3) | 7 (58.3) | 1.0 |
*Included only antibiotics for treatment
Values are presented as mean± standard error unless specified. T-Test or Chi-square/Fisher’s exact performed where appropriate. HT = heart transplant, LVAD = left ventricular assist device, BMI = body mass index, AST = aspartate aminotransferase, Afib = atrial fibrillation.